A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda

被引：0
|
作者：
Solomon J. Lubinga
Byamah B. Mutamba
Angelo Nganizi
Joseph B. Babigumira
机构：
[1] University of Washington,Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy
[2] University of Washington,Global Medicines Program, Department of Global Health
[3] Butabika National Referral Hospital for Mental,undefined
[4] Neurological and Substance Abuse Disorders,undefined
[5] Kadic Hospital,undefined
来源：
Applied Health Economics and Health Policy | 2015年 / 13卷
关键词：
Schizophrenia; Haloperidol; Risperidone; Olanzapine; Quetiapine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：493 / 506
页数：13
相关论文
共 50 条
  • [1] A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda
    Lubinga, Solomon J.
    Mutamba, Byamah B.
    Nganizi, Angelo
    Babigumira, Joseph B.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2015, 13 (05) : 493 - 506
  • [2] Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
    Park, Taehwan
    Kuntz, Karen M.
    VALUE IN HEALTH, 2014, 17 (04) : 310 - 319
  • [3] A cost-effectiveness clinical decision analysis model for treatment of schizophrenia
    Palmer, CS
    Brunner, E
    Ruíz-Flores, LG
    Paez-Agraz, F
    Revicki, DA
    ARCHIVES OF MEDICAL RESEARCH, 2002, 33 (06) : 572 - 580
  • [4] Cost-effectiveness simulation analysis of schizophrenia at the Instituto Mexicano del Seguro Social: Assessment of typical and atypical antipsychotics
    Mould-Quevedo, Joaquin
    Contreras-Hernandez, Iris
    Verduzco, Wascar
    Manuel Mejia-Arangure, Juan
    Garduno-Espinosa, Juan
    REVISTA DE PSIQUIATRIA Y SALUD MENTAL, 2009, 2 (03): : 108 - 118
  • [5] RETURNING TO THE ISSUE OF THE COST-EFFECTIVENESS OF ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA
    Ohlsen, Ruth
    Taylor, David
    Tandon, Kopal
    Aitchison, Katherine
    CLINICAL NEUROPSYCHIATRY, 2008, 5 (04): : 184 - 194
  • [6] Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
    Furiak N.M.
    Ascher-Svanum H.
    Klein R.W.
    Smolen L.J.
    Lawson A.H.
    Conley R.R.
    Culler S.D.
    Cost Effectiveness and Resource Allocation, 7 (1)
  • [7] Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
    Antonio J García-Ruiz
    Lucía Pérez-Costillas
    Ana C Montesinos
    Javier Alcalde
    Itziar Oyagüez
    Miguel A Casado
    Health Economics Review, 2 (1)
  • [8] Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses
    Garcia-Ruiz, Antonio J.
    Perez-Costillas, Lucia
    Montesinos, Ana C.
    Alcalde, Javier
    Oyagueez, Itziar
    Casado, Miguel A.
    HEALTH ECONOMICS REVIEW, 2012, 2
  • [9] Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK
    Davies, Andrew
    Vardeva, Kawitha
    Loze, Jean-Yves
    L'Italien, Gilbert J.
    Sennfalt, Karin
    van Baardewijk, Marc
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3275 - 3285
  • [10] Cost-effectiveness in the treatment of schizophrenia
    Knapp, MRJ
    EUROPEAN PSYCHIATRY, 1996, 11 (03) : 137 - 143
12345